Hemo Organic Limited (HEMORGANIC) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Hemo Organic Limited ₹36.41, price ₹21.88, upside +66.4%, quality 24 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹5.86 – ₹77.15 · fair‑value band ₹23.95 – ₹45.04 · the ₹21.88 price screens below the ₹36.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Hemo Organic in your weekly email
Every Wednesday you see whether Hemo Organic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hemo Organic Limited engages in the manufacture and sale of ayurvedik or Unani pharmaceutical preparations in India. It also engages in the manufacturing, trading, and dealing of chemicals, dyes, pigments, auxiliaries, intermediates, heavy and fine chemicals, organic and inorganic chemicals, etc.
Show more
Hemo Organic Limited engages in the manufacture and sale of ayurvedik or Unani pharmaceutical preparations in India. It also engages in the manufacturing, trading, and dealing of chemicals, dyes, pigments, auxiliaries, intermediates, heavy and fine chemicals, organic and inorganic chemicals, etc. The company was formerly known as Dinesh Allorga Limited and changed its name to Hemo Organic Limited in August 2013. The company was incorporated in 1992 and is based in Anand, India.
Stock analysis
Hemo Organic Limited (HEMORGANIC) currently trades at ₹21.88, while our model-based Fair Value estimate is ₹36.41, implying the stock looks roughly 39.9% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹23.95 (bear) to ₹45.04 (bull), the price of ₹21.88 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hemo Organic Limited reported revenue of ₹9.3M in FY2026 versus ₹68.3K in FY2022, a compound +241.5%/yr. Reported net income was −₹7.8M in FY2026.
Key figures
Market cap ₹75.8M (≈ $787K) · P/S ratio 7.77 · EPS (TTM) ₹−2.20 · Net margin −83.8% · Return on assets (EBIT) −15.4% · Operating margin −49.3% · Revenue (TTM) ₹9.3M · Revenue growth (YoY) −62.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 169% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 66%, HEMORGANIC screens cheaper than that median.
Fair Value models
Bear ₹23.95Fair Value ₹36.41Bull ₹45.04
Price ₹21.88 · Upside +66.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−61.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+478.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+158.4%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.9%
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−591.5% (2021) → −54.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside+66.4% · Top 25%
Profitability
Return on assets−6.6% · Bottom 25%
Net margin (TTM)−82.5% · Bottom 25%
Operating margin (TTM)−49.3% · Bottom 25%
Growth and dividend
Revenue growth−62.7% · Bottom 25%
Balance sheet
Debt / equity20.62× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hemo Organic Limited (HEMORGANIC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹36.41 versus a price of ₹21.88, about +66% upside (undervalued).
What is the fair value of HEMORGANIC?
Our model-based fair value for Hemo Organic Limited is ₹36.41 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹21.88.
What is the quality score of HEMORGANIC?
Hemo Organic Limited has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hemo Organic Limited (HEMORGANIC)?
Our model-based price target is the fair value of ₹36.41 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario ₹23.95, optimistic scenario ₹45.04. It is a calculation from audited fundamentals, not an analyst target.
What is the Hemo Organic Limited stock forecast for 2026?
Our models put fair value at ₹36.41, about +66% upside versus a price of ₹21.88 (undervalued). Cautious scenario ₹23.95, optimistic scenario ₹45.04. The calculation is refreshed regularly with new filings.
What is the revenue of Hemo Organic Limited (HEMORGANIC)?
Hemo Organic Limited reported trailing-twelve-month revenue of about ₹9.3M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Hemo Organic Limited (HEMORGANIC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hemo Organic Limited it is ₹36.41 per share (as of Sep 27, 2026), against a price of ₹21.88. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Hemo Organic Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, HEMORGANIC trades below its calculated fair value: price ₹21.88, fair value ₹36.41, a gap of about +66% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HEMORGANIC?
No. The price is what the market pays today (₹21.88); the fair value is what the company's own numbers justify (₹36.41). For Hemo Organic Limited the two are ₹14.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hemo Organic Limited worth?
The market values Hemo Organic Limited at about ₹75.8M (market capitalisation, as of Sep 27, 2026). Per share that is ₹21.88; our models calculate a fair value of ₹36.41 per share.
What do the bullish and bearish scenarios say about HEMORGANIC?
Our models span a range for Hemo Organic Limited: cautious scenario ₹23.95, base ₹36.41, optimistic ₹45.04 per share (as of Sep 27, 2026, price ₹21.88). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is HEMORGANIC from its 52-week high?
Hemo Organic Limited trades at ₹21.88, about 10% below its 52-week high of ₹24.42 and 169% above the low of ₹8.12 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹36.41 is for.
Which stocks are comparable to Hemo Organic Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hemo Organic Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹21.88, calculated fair value ₹36.41 (+66%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HEMORGANIC calculated?
We run Hemo Organic Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹36.41, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Hemo Organic Limited currently trades 40 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hemo Organic Limited (HEMORGANIC)?
The closing price on Oct 1, 2026 was ₹21.88. Our model-based fair value is ₹36.41, about +66% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hemo Organic Limited right now?
The large discount to fair value meets weak quality (24/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹23.95). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹23.95 to ₹45.04) leaves room in how you read the outcome.
Key figures of Hemo Organic Limited
How large is the market capitalisation of Hemo Organic Limited (HEMORGANIC)?
The market capitalisation of Hemo Organic Limited is ₹75.8M (≈ $787K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hemo Organic Limited (HEMORGANIC)?
The price-to-sales ratio of Hemo Organic Limited is 7.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hemo Organic Limited (HEMORGANIC)?
Earnings per share at Hemo Organic Limited are ₹−2.20. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hemo Organic Limited (HEMORGANIC)?
The net margin of Hemo Organic Limited is −83.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Hemo Organic Limited (HEMORGANIC)?
On an EBIT basis the return on assets of Hemo Organic Limited is −15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hemo Organic Limited (HEMORGANIC)?
The operating margin of Hemo Organic Limited is −49.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hemo Organic Limited (HEMORGANIC)?
Revenue at Hemo Organic Limited is growing −62.7% versus a year earlier (3y avg +478%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hemo Organic Limited (HEMORGANIC) generate?
The free cash flow of Hemo Organic Limited is −₹14.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hemo Organic Limited (HEMORGANIC) carry?
The net debt of Hemo Organic Limited is ₹27.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hemo Organic Limited in the live analysis
One click puts Hemo Organic Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
